Figure 1.

NCL-1 efficiently suppresses neuroblastoma cell viability in vitro and inhibits KDM1A-mediated histone demethylation. (A). The effective dose of NCL-1 required to inhibit cell viability by 50% (EC₅₀) was calculated for the human neuroblastoma cell lines SH-EP, SK N BE, SK-N-AS, and IMR-5. The EC₅₀ and the inhibitory concentration (IC₅₀) values were identical. Cell viability was assessed using the MTT assay after treatment with 5–80 µM NCL-1 for 72 h. Treatment with the solvent (DMSO) alone served as the control. (B) Whole-cell lysates were prepared in RIPA buffer from cultures treated with 40 µM NCL-1 or DMSO (control) for 24 h and 72 h, then sonicated to disrupt protein complexes. Relative KDM1A activity was analyzed using the EpiQuik™ KDM1A/LSD1 activity/inhibition assay. Significant differences between treatment groups were assessed by Student’s t-test. All comparisons between treatment groups and the corresponding controls had p-values < 0.001. *** p < 0.0001.